In early 2026, Dr. Anya Sharma, who heads vaccine development at BioGen Pharmaceuticals in Bangalore, had a massive problem. Demand for their new Nipah vaccine, NV-2026, was about to blow past their manufacturing capacity by 300% in under six months. With real outbreaks happening in Southeast Asia and the WHO demanding a huge, fast deployment, this wasn’t some academic projection. So how does a notoriously slow and cautious industry suddenly find a way to work at pandemic speed?
Key Takeaways
- To keep up with new infectious diseases, global vaccine manufacturing has to grow by at least 25% a year.
- The WHO’s mRNA Technology Transfer Hub in South Africa had trained scientists from 15 low- and middle-income countries by early 2026, jump-starting local production.
- Contract Development and Manufacturing Organizations (CDMOs) like Lonza and Catalent are essential partners, now handling over 40% of the world’s vaccine fill-and-finish work.
- There’s a critical shortage of biosafety level 3 (BSL-3) labs in places like Latin America and Africa, a bottleneck that needs an estimated $500 million in new infrastructure over the next five years.
- Standardized regulatory paths, like the ones being tested by the International Coalition of Medicines Regulatory Authorities (ICMRA), can cut vaccine approval times by up to six months.
| Factor | BioGen’s Current Capacity | Projected Demand (WHO) |
|---|---|---|
| NV-2026 Doses (Annual) | 50 million | 150 million (initial request); 500 million (global spread) |
| Time Horizon for Shortfall | 6 months | Not applicable |
| Efficacy (late-stage trials) | 95% | Not applicable |
| Manufacturing Model | Single-company facility | Distributed manufacturing. CDMO partnerships |
The Looming Shortfall: Dr. Sharma’s Dilemma
The science behind NV-2026 was solid, Dr. Sharma’s team at BioGen had produced a modified vaccinia Ankara (MVA) vector vaccine with 95% efficacy in late-stage trials. The real problem was scale. BioGen’s facility, while modern, could only make about 50 million doses a year. The WHO was asking for 150 million doses to start, with a warning that it could climb to 500 million if the virus went global. As Dr. Sharma told her team, “We have the recipe, but we don’t have enough kitchens.”
This wasn’t just BioGen’s problem. Everyone remembered how the COVID-19 pandemic shattered global vaccine supply chains. Wealthy countries used advance purchase agreements to jump to the front of the line, leaving most low- and middle-income countries (LMICs) waiting. That history is exactly why the WHO was now pushing for distributed manufacturing. Reading the latest WHO situation report, Dr. Sharma knew the world couldn’t afford a repeat of vaccine nationalism.
The WHO’s Strategic Pivot: Decentralizing Production
Having learned hard lessons from past crises, the WHO was already putting its new strategy into action. The mRNA Technology Transfer Hub in South Africa, set up back in 2021, was a perfect example. By early 2026, a WHO report on global vaccine equity confirmed the hub had trained more than 200 scientists and technicians from 15 different LMICs. They were learning the entire mRNA production process, from plasmid DNA synthesis all the way to lipid nanoparticle formulation, and then taking that knowledge home to build local capacity.
As WHO Director-General Dr. Tedros Adhanom Ghebreyesus said in a press briefing, “Our goal is to deliver vaccines and to help countries to produce their own. This builds resilience and ensures equitable access for when the next pathogen emerges.” This was a huge change from the old model where a few big manufacturers in developed countries made everything. The WHO had seen that relying on that small group was a recipe for disaster in a global health crisis.
BioGen’s Search for Partners: The CDMO Solution
For BioGen, the only path forward was partnerships. Dr. Sharma knew building new plants would take years and cost billions, time and money they didn’t have. So, her team turned its focus to Contract Development and Manufacturing Organizations (CDMOs), specialized firms with the infrastructure and expertise to make drugs for other companies.
Finding the right CDMO meant looking for a partner that could deliver capacity, quality, and speed, all while working through regulatory compliance in multiple countries. BioGen started talking with global players like Lonza and Catalent, who had deep experience in vaccine work. This outsourcing model was becoming standard. A late 2025 report from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) showed that CDMOs were already handling over 40% of global vaccine fill-and-finish work. It’s clear that pharma companies are focusing more on R&D and letting manufacturing specialists handle the capital-heavy production.
“The complexity of scaling up a novel vaccine like NV-2026, especially one requiring BSL-3 containment for certain stages, means we can’t afford any missteps,” Dr. Sharma explained to her board. “A CDMO with established BSL-3 facilities and a track record of rapid tech transfer is non-negotiable.” That single requirement made their search much harder. Plenty of CDMOs had capacity, but BSL-3 compliance is a whole other level of cost and complexity, and it put a spotlight on a global infrastructure gap. Many regions simply don’t have enough high-containment labs.
Overcoming Infrastructure Gaps: The BSL-3 Bottleneck
Any talk about scaling vaccine production quickly runs into the problem of infrastructure, specifically biosafety level 3 (BSL-3) laboratories. You need these facilities to safely work with pathogens that can kill you if you inhale them. A 2024 analysis by the Coalition for Epidemic Preparedness Innovations (CEPI) found a huge shortfall of BSL-3 capacity, particularly in sub-Saharan Africa and parts of Latin America. The report put a number on it: at least $500 million in new investment is needed over the next five years, and most experts think that’s a lowball estimate.
For NV-2026, certain production steps like seed virus propagation had to be done under BSL-3 conditions. This meant a potential CDMO partner could have empty bioreactors ready to go, but if they didn’t have the right biosafety setup, the deal was a non-starter. This is why international collaboration is so important. Big players like the World Bank and regional development banks are finally funding more biosafety projects, seeing them as a core part of global health security for manufacturing, surveillance, and research.
We’re starting to see some progress with regional BSL-3 training centers that are often built alongside existing research institutes. The Pasteur Institute in Dakar, Senegal, for example, has expanded its BSL-3 training program and is now drawing scientists from all over West Africa. It’s these kinds of programs that build up the expertise and the facilities needed for real distributed vaccine production.
Regulatory Harmonization: A Speed Bump or a Superhighway?
Even after you solve the manufacturing problem, you run straight into the next wall: regulatory hurdles. Every country’s health authority has its own process, its own paperwork, and its own requirements for local trials. This patchwork system can easily add months, sometimes a year, before a vaccine gets to the people who need it. Dr. Sharma knew this pain from past projects where the science was done but the bureaucracy was just getting started.
The WHO has been working with the International Coalition of Medicines Regulatory Authorities (ICMRA) to get everyone on the same page. By 2026, pilot programs for simplified, mutually recognized approvals were running. One joint review, involving the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and several African national agencies, showed it was possible to slash approval times by as much as six months for a critical vaccine. This international cooperation gets shots into arms faster and saves lives.
“The data package for NV-2026 is strong,” Dr. Sharma noted during a call with regulatory affairs specialists. “If we can use these new harmonized pathways, we could cut our time-to-market in key regions by a quarter. That’s an operational win and an ethical imperative.” The big political and logistical challenge, of course, is getting all 194 WHO member states to actually adopt and trust these new frameworks.
The Future of Global Vaccine Production: A Distributed Network
By late 2026, BioGen had pulled it off. They locked in a partnership with a major CDMO, which tripled their initial production capacity for NV-2026. The WHO’s COVAX facility and its new regional initiatives placed pre-orders, giving BioGen the financial security to scale even further. The first shipments of NV-2026 were finally on their way to the affected regions, a tangible result of a massive, coordinated global push.
What Dr. Sharma went through shows that the future of vaccine production can’t be about a single factory in one country. It has to be a tough, distributed network of manufacturing sites supported by solid supply chains, harmonized regulations, and a skilled global workforce. The WHO’s drive for technology transfer and regional hubs is a pragmatic response to a world facing more frequent and dangerous infectious disease threats. The goal is to shift from a panicked, reactive scramble to a proactive, integrated global response, making sure no country gets left at the back of the line again.
Making this happen will take consistent investment, real political will, and non-stop collaboration. It means pushing for better vaccine platforms, reinforcing public health systems, and making sure everyone has access to raw materials and expertise. Whether we win or lose against the next pandemic will come down to how well we can produce and deliver vaccines at scale, everywhere, without hesitation. For more on the data side of these health crises, see our article on fixing mortality data gaps for 2026 health crises.
What’s so hard about scaling up vaccine production globally?
You run into a few big walls: not enough factory capacity (especially for new tech like mRNA), shortages of raw materials and gear, not enough trained people, and a messy web of different regulatory rules in every country.
What’s the WHO doing about vaccine inequality?
They’re backing initiatives like the mRNA Technology Transfer Hub in South Africa to train scientists and share tech with low- and middle-income countries. They’re also pushing for global partnerships and funding to build up regional factories and help local regulators get up to speed.
What’s the point of a CDMO in vaccine production?
CDMOs are a huge help because they have the specialized factories, people, and capacity that the original drug developers might not have. They can handle everything from making the active ingredient to filling the vials, which lets the innovators focus on R&D.
What’s a BSL-3 lab and why do you need it for vaccines?
A Biosafety Level 3 (BSL-3) lab is a high-containment facility for handling dangerous pathogens you could get through inhalation. For certain vaccines made from highly pathogenic viruses, you absolutely need a BSL-3 facility to keep workers and the environment safe during production.
How does getting regulators to agree with each other speed things up?
When regulators harmonize, using things like joint reviews or recognizing each other’s approvals, it cuts out a ton of redundant paperwork and testing. This means a safe and effective vaccine can get approved and distributed in many countries much faster.
